Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
$14.73
$14.71
$11.53
$15.89
$214.06M1.43111,205 shs79,779 shs
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$1.03
$1.01
$0.32
$1.57
$211.41M2.151.93 million shsN/A
XOMA Co. stock logo
XOMA
XOMA
$26.09
+1.0%
$24.56
$13.48
$27.00
$303.69M0.5821,196 shs11,780 shs
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
$1.08
$0.77
$5.95
$187.12M1.712.01 million shs2.13 million shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
+0.07%+0.34%-0.41%+12.02%+20.84%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00%0.00%0.00%0.00%+46.85%
XOMA Co. stock logo
XOMA
XOMA
+1.33%+6.08%+4.11%+30.73%+38.97%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
XOMA Co. stock logo
XOMA
XOMA
3.6371 of 5 stars
3.52.00.03.02.41.70.6
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
2.00
HoldN/AN/A
XOMA Co. stock logo
XOMA
XOMA
3.00
Buy$74.00183.63% Upside
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A

Current Analyst Ratings

Latest ZIOP, MACK, SPPI, and XOMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/16/2024
XOMA Co. stock logo
XOMA
XOMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$74.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/A$1.31 per shareN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$10.11M20.91N/AN/A$0.15 per share6.87
XOMA Co. stock logo
XOMA
XOMA
$4.76M63.80N/AN/A$7.72 per share3.38
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A$0.58 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
-$1.18M-$0.08N/AN/AN/A-6.24%-6.09%5/2/2024 (Estimated)
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/A
XOMA Co. stock logo
XOMA
XOMA
-$40.83M-$4.04N/AN/AN/A-886.91%-25.17%-17.08%5/14/2024 (Estimated)
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/A

Latest ZIOP, MACK, SPPI, and XOMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/8/2024Q4 2023
XOMA Co. stock logo
XOMA
XOMA
-$0.36-$0.49-$0.13$0.89$1.01 million$1.83 million
3/7/2024Q4 2023
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/A-$0.01-$0.01-$0.01N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/AN/AN/AN/AN/A
XOMA Co. stock logo
XOMA
XOMA
N/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/A
43.50
43.50
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/A
2.71
2.38
XOMA Co. stock logo
XOMA
XOMA
1.34
8.68
8.68
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.18
3.43
3.43

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
63.97%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
21.67%
XOMA Co. stock logo
XOMA
XOMA
95.92%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
51.03%

Insider Ownership

CompanyInsider Ownership
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
28.87%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
2.70%
XOMA Co. stock logo
XOMA
XOMA
7.20%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
5.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
42614.53 million10.09 millionOptionable
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
86205.25 million199.70 millionOptionable
XOMA Co. stock logo
XOMA
XOMA
1311.64 million10.80 millionOptionable
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
105216.15 million204.91 millionOptionable

ZIOP, MACK, SPPI, and XOMA Headlines

SourceHeadline
Childhood CancersChildhood Cancers
curetoday.com - February 17 at 5:57 PM
Alx Oncology Holdings (ALXO)Alx Oncology Holdings (ALXO)
investing.com - February 10 at 8:15 PM
Pediatric Hematology-Oncology FellowshipPediatric Hematology-Oncology Fellowship
bcm.edu - February 5 at 8:39 AM
Alaunos Therapeutics: Other Events, Financial Statements And ExhibitsAlaunos Therapeutics: Other Events, Financial Statements And Exhibits
cbonds.com - January 31 at 9:44 AM
CG Oncology IncCG Oncology Inc
reuters.com - January 31 at 4:43 AM
Oncology Nurses Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer PatientsOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients
medscape.com - December 21 at 3:43 PM
Immuno-OncologyImmuno-Oncology
ajmc.com - December 19 at 3:21 PM
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
markets.businessinsider.com - December 18 at 8:18 AM
Exploring Patient-Centered Handoffs in Surgical OncologyExploring Patient-Centered Handoffs in Surgical Oncology
medscape.com - December 10 at 7:36 PM
Association of Community Cancer CentersAssociation of Community Cancer Centers
ajmc.com - October 14 at 2:50 PM
Oncology News and ResearchOncology News and Research
news-medical.net - September 19 at 5:53 PM
WBSPH 2024 - OncologyWBSPH 2024 - Oncology
newsweek.com - September 15 at 8:49 PM
Kris on OncologyKris on Oncology
medscape.com - September 6 at 11:16 PM
Gauging Ziopharms Chances for Positive Sarcoma Drug Trial ResultsGauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results
thestreet.com - August 29 at 6:23 AM
Oncology Cases & QuizzesOncology Cases & Quizzes
medscape.com - August 14 at 6:15 PM
Ziopharm’s palifosfamide fails in first-line STS…Ziopharm’s palifosfamide fails in first-line STS…
investing.com - June 21 at 12:05 AM
Weber on OncologyWeber on Oncology
medscape.com - June 19 at 2:11 PM
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in MelanomaA Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma
ascopubs.org - June 17 at 8:43 AM
ALX Oncology Holdings Inc Ordinary SharesALX Oncology Holdings Inc Ordinary Shares
morningstar.com - June 15 at 6:54 PM
Division of Pediatric Hematology and OncologyDivision of Pediatric Hematology and Oncology
slu.edu - June 13 at 3:50 PM
Division of Hematology and Medical OncologyDivision of Hematology and Medical Oncology
slu.edu - June 13 at 3:50 PM
Intratumoral Cancer Therapies Global Market Report 2023Intratumoral Cancer Therapies Global Market Report 2023
finance.yahoo.com - June 9 at 1:32 PM
Natural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.coNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.co
marketwatch.com - May 11 at 9:52 PM
VC Identifies 3 Startups That Will Shake Up the Future of Cancer CareVC Identifies 3 Startups That Will Shake Up the Future of Cancer Care
medcitynews.com - May 10 at 1:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Merrimack Pharmaceuticals logo

Merrimack Pharmaceuticals

NASDAQ:MACK
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Spectrum Pharmaceuticals logo

Spectrum Pharmaceuticals

NASDAQ:SPPI
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.
XOMA logo

XOMA

NASDAQ:XOMA
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
ZIOPHARM Oncology logo

ZIOPHARM Oncology

NASDAQ:ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.